26/10/2001
ReGen Therapeutics Plc reports that it has completed the recruitment of patients to its current limited clinical trial of Colostrinin™ as a potential drug in the treatment of Alzheimer’s disease.
The trial is being conducted at six clinical centres in Poland. The last patient has been admitted to the study and will complete the double blind, placebo-control phase at the end of January 2002. The International Steering Committee is expected to meet in February 2002 to assess the data for all patients at that stage of the trial and ReGen will make an announcement on the findings following that meeting.
Final results from the full trial, following completion by all patients of the second, open label phase, are now expected in May 2002. Following a further review by the International Steering Committee of the resultant data and assuming an encouraging indication of efficacy and no adverse findings by the Committee, ReGen anticipates beginning thereafter to seek potential licensees or commercial partners for the further development of Colostrinin™.